FDA Accepts Resubmitted BLA for Outlook's Wet AMD Treatment, Sets July 29 PDUFA Date

Event summary

  • FDA accepted Outlook Therapeutics' resubmitted BLA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat wet AMD, classifying it as a Class 1 review.
  • The PDUFA target action date is July 29, 2026.
  • If approved, ONS-5010/LYTENAVA™ will be the first FDA-approved ophthalmic formulation of bevacizumab with standardized manufacturing and labeling.
  • Outlook has already initiated pre-launch activities in anticipation of potential approval.

The big picture

Outlook Therapeutics is seeking to establish LYTENAVA™ as the first FDA-approved ophthalmic formulation of bevacizumab, addressing a significant unmet need in wet AMD treatment. The strategic move comes as the biopharmaceutical industry increasingly focuses on standardized, regulated alternatives to off-label therapies. Success here could set a precedent for other biosimilars targeting niche indications.

What we're watching

Regulatory Approval
Whether the FDA will approve ONS-5010/LYTENAVA™ by the July 29 PDUFA date, clearing the path for commercialization in the U.S.
Market Differentiation
How Outlook positions LYTENAVA™ against existing off-label uses of bevacizumab in wet AMD, leveraging its FDA-approved status.
Commercial Execution
The pace at which Outlook can scale pre-launch activities and secure pricing and reimbursement approvals in key European markets.

Related topics

Biotechnology